Breast Cancer

  1. Ibrance (palbociclib)
    Ibrance (palbociclib)
    by Pfizer Limited
    for Breast Cancer
    €4,594.25
  2. Kisqali (ribociclib)
    Kisqali (ribociclib)
    by Novartis Europharm Limited
    for Breast Cancer
    €4,887.50
  3. Lynparza (olaparib)
    Lynparza (olaparib)
    by AstraZeneca AB
    for Breast Cancer, Gynaecological Cancer
    €6,619.40
  4. Perjeta (pertuzumab)
    Perjeta (pertuzumab)
    by Roche Registration Limited
    for Breast Cancer
    €2,869.25
View as Grid List

4 Items

per page
Set Descending Direction

Just one thing before you continue

Our service contains information about acquiring treatments that have been approved in another country. This includes professional information such as approval details, product information and pricing. By scrolling, you are declaring that you are requesting any such information.

No, take me out of here.
CONTINUE